Technology Sourcing: Are Biotechnology Firms Different? An Exploratory Study of the Spanish Case by Holl, Adelheid & Rama, Ruth
 
 
 
 
INDUSTRY STUDIES ASSOCATION 
WORKING PAPER SERIES 
 
 
Technology Sourcing: Are Biotechnology Firms Different?  
An Exploratory Study of the Spanish Case 
 
By 
 
Adelheid Holl 
Institute of Public Goods and Policies (IPP) 
CSIC - Consejo Superior de Investigaciones Científicas 
C/ Albasanz, 26-28;  28037 Madrid, Spain 
adelheid.holl@cchs.csic.es 
 
And 
 
Ruth Rama  
Institute of Economics, Geography and Demography (IEGD) 
CCHS-CSIC (Spanish Council for Scientific Research) 
C/ Albasanz, 26-28;  28037 Madrid, Spain 
ruth.rama@cchs.csic.es 
 
 
 
 
 
 
 
 
 
 
2011 
Industry Studies Association 
Working Papers 
 
WP-2011-01 
http://isapapers.pitt.edu/ 
 1 
 
Technology sourcing: Are biotechnology firms different? An 
exploratory study of the Spanish case*
 
 
Adelheid Holl 
Institute of Public Goods and Policies (IPP) 
CSIC - Consejo Superior de Investigaciones Científicas 
C/ Albasanz, 26-28;  28037 Madrid, Spain 
adelheid.holl@cchs.csic.es 
 
 
Ruth Rama  
Institute of Economics, Geography and Demography (IEGD) 
CCHS-CSIC (Spanish Council for Scientific Research) 
C/ Albasanz, 26-28;  28037 Madrid, Spain 
ruth.rama@cchs.csic.es 
 
 
 
 
Abstract:  
 
In this paper, we study the pattern of technology sourcing, taking into account where 
firms’ source technology and through which channels. We specifically, inquire whether 
biotechnology firms are different from other firms in their technology sourcing 
behaviour. Our results show some significant differences in the patterns of technology 
sourcing. Biotechnology firms show a greater propensity for external technology 
sourcing both with regard to the external purchasing of R&D services and with regard 
to cooperation for innovation. They also show a greater propensity for foreign R&D 
purchasing relations but they are, not more likely to establish foreign cooperation for 
innovation once we control for their firm-specific and industry characteristics as well as 
sample selection bias. Biotechnology firms do, however, show a more varied pattern of 
sourcing both concerning the types of agents and the geographic origin of technology. 
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1. Introduction 
 
Biotechnology is one of those emerging fields of innovation which may have the 
potential to radically transform other industries and economic activities, such as 
agriculture, the food and drink industry, or pharmaceuticals.  In today’s fast-paced, 
knowledge-intensive environment, however, innovation is rarely the outcome of firms 
own internal R&D efforts. Innovation is increasingly the outcome of interactions among 
multiple actors and both R&D outsourcing as well as networking for R&D have become 
significant features in current innovation management as ways to develop and gain 
access to new technologies. At the same time, the technology necessary for global 
competitiveness is often dispersed internationally. In this context, international R&D 
networks can provide firms with access to country-specific advantages and allow them 
to tap into the comparative advantages of foreign countries. While technology transfer 
is now recognized among economists and policymakers as key for economic growth, 
there is still relatively little knowledge at the firm level on the patterns of technology 
sourcing and the mechanisms underlying technology transfer. 
 
In this paper we focus on the biotechnology sector in order to study the boundaries of 
innovative networks and the plurality of actors (e.g. firms, public administration, 
universities and research centres) involved in innovation. Biotechnology is faced with a 
complex knowledge base and rapid technological development. Powell et al. (1996) 
characterize the industry as one where innovations are therefore to a greater degree 
the outcome of networks of learning compared to other industries. 
 
We study the sourcing of technology, taking into account where the firms source 
technology and through which channels. The paper contributes to the literature on 
technology sourcing first by assessing the relative importance of national versus 
international linkages of technology sourcing in general, and specifically in the 
biotechnology sector. Secondly, we explore whether technology sourcing through 
contracts or purchases may involve different spatial patterns than the sourcing of 
technology via cooperation, as well as its relation to the type of partner. Thirdly, we 
inquire whether biotechnology firms are different from other firms in their technology 
sourcing behaviour. 
 
Our analysis is related to the literature on knowledge spillovers and technology 
transfer. This body of literature has shown its importance for innovative activity, 
productivity and competitiveness. Past studies have also underlined that knowledge 
spillovers are geographically localised. Not denying the role of space for knowledge 
flows, recent studies, nevertheless show that knowledge flows are not necessarily 
bounded by national borders (Malerba et al., 2007). In this sense, the micro-economic 
literature has highlighted different channels for the international transmission of 
technological knowledge: imports of new capital and differentiated intermediate goods, 
learning by exporting, foreign investment by multinationals (Zhu and Jeon, 2007), and 
the movements of workers (Markusen and Trofimenko, 2009) and specifically 
scientists. International networks of cooperation and international R&D purchasing are 
further catalysts for knowledge transfer across borders. A better understanding of the 
factors related to such international technology sourcing decisions will also contribute 
to the analysis of international knowledge spillovers. 
 
Another related body of literature has focused on cross-border regional innovation 
systems (Tripple, 2010). An important question here is under which conditions regional 
innovation systems can transcend national borders. Our research can contribute to this 
strand of literature by providing insights into the patterns of different types of 
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technology sourcing relations. Though the technology sourcing of some industries has 
deserved the interest of scholars, quantitative research on the possible specificity of 
industries which are at the forefront of sciences and techniques are rare.   
 
Research cooperation is at the heart of EU innovation policy which aims to create a 
single European Research Area. A central objective is to make it easier for knowledge 
and technologies to circulate freely, especially in emerging high tech industries, such 
as biotechnology.  
 
 
2.  Literature review  
 
Technology is becoming increasingly complex, multi-disciplinary and dynamic. For 
technology intensive firms such as biotechnology firms this means that developing all 
necessary technological know-how internally is increasingly costly (Powell et al. 1996; 
Cooke, 2005; Nilsson, 2001). Thus, to cope with this situation and stay competitive, 
firms rely on necessary knowledge from other firms (Hagedoorn, 1993). Herstad et al 
(2010) suggest that the importance of external knowledge sourcing may be increasing.  
More specifically, Hagedoorn and Narula (1996) and Hagedoorn (2002) provide 
evidence on the rise of technology sourcing cooperation over the past decades. 
Hopkins et al. (2007) argue that alliances and outsourcing linkages seem to be 
common since the end of the 1990s in the biotechnology sector. In the biotechnology 
industry, alliances may help to speed up R&D activities; and provide access to new 
knowledge and to R&D funding (Suárez-Villa and Walrod, 2003).  By the same token, 
R&D outsourcing may be instrumental in cost savings (Suárez-Villa and Walrod, 2003).  
In pharma- biotechnology, the high cost of R&D, the decline of R&D productivity and 
the need to coordinate a complex knowledge base have stimulated the emergence of 
an increasingly networked industry (Powell et al 2005). Another study shows that a 
distributed innovation system is also the norm in the European agro-food biotech 
industry (Senker and Mangematin, 2008). 
 
The external sourcing of technology (hereafter, the sourcing of technology) includes a 
wide range of arrangements such as: arms-length licensing arrangements, research 
contracts, joint development agreements, joint ventures, etc. 
 
In this paper we study two alternative mechanisms that firms can use to acquire 
knowledge externally.  
 
o R&D external acquisitions includes either the purchase of R&D 
services through arm-length contracts or through outsourcing 
relationships meaning that task and processes are contracted to a 
third party company. 
o Cooperative arrangements. Two or more separate organisations join 
forces to share and develop knowledge in order to enhance their 
innovative performance. 
 
The second dimension that we study in this paper is the spatial extent of these 
relations. Herstad et al. (2010) observe the rise of “globally distributed knowledge 
networks” (p. 116).  Since the second half of the nineties, the growing phenomenon of 
globally distributed work organization has brought with it also a rise in international 
R&D sourcing and international collaboration for innovation. For instance, while in 1990 
10% of all patent applications filed at the European Patent Office listed at least one 
inventor located in a different country than the applicant, this figure had risen to 18% by 
2004 (Abramovsky et al., 2008). Robles et al. (2009) provide evidence on the general 
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rise of international partnerships during the 1990’s among Spanish firms. Our research 
compares national and international technology sourcing relations. 
 
Powell et al. (1996) argue that different forms of R&D cooperation are particularly 
relevant for innovation in the biotechnology sector, given that the sector is 
characterized by a complex knowledge base and rapid technological development. 
New industries based on emerging fields of innovation have been argued to adopt 
specific forms of organisation (Hopkins et al., 2007). For instance, such emerging fields 
often rely initially on contributions made by universities and government labs, while 
private companies may play a limited role in innovation (Miyazaki and Islam, 2007). 
This circumstance, in our view, can make contacts with academic laboratories 
particularly important for these firms.  Sectoral studies of innovation indicate that 
aspects related to R&D network structure and composition are insufficiently explored in 
the literature (Malerba, 2005).  A special concern is, in our view, whether new science-
based industries promote new types of arrangements in R&D networks. Are these 
emerging networks different from those prevailing in other industries? There is not 
much quantitative research on this topic.  However, the available evidence seems to 
support the idea that they are fundamentally different.  Analysing French firms, Miotti 
and Sachwald (2003) note, for instance, that companies conducting research at the 
technological frontier are more likely to cooperate; and they are more prone to engage 
in transatlantic collaboration.  Using Community Innovation Survey (CIS) data for a 
pooled sample of manufacturing and service firms from France, Germany, Ireland and 
Spain, Mohnen and Hoareau (2002) also find that R&D collaborations are more 
frequent among firms belonging to the scientific sectors.  These analyses provide 
important insights at the sector level.  However, emerging industries are based on 
radically new products or ideas.  Usually there is not yet a specific industrial 
classification containing these economic activities and, therefore, information is 
disseminated in a variety of sectors (we come back to this question below).  This 
situation poses a statistical difficulty to researchers conducting quantitative analyses of 
such industries (see, for instance, Benneworth, 2003). Fine grained studies focusing on 
the specificity of linkages developed by firms active in emergent industries (e.g. 
biotechnology) are, therefore, still rarer. Nevertheless, case studies need to be 
complemented by statistical analyses which may help to understand the technology 
sourcing of these emerging industries. 
 
In this paper, we compare the different modes for technology sourcing between 
biotechnology firms and firms with no biotechnology activity in order to test whether 
biotechnology firms are really different in their technology sourcing behaviour. 
 
 
3. Data 
 
Our data comes from a survey of Spanish firms (Panel de Innovación Tecnológica, 
PITEC) collected by the Spanish National Statistics Institute (INE). The PITEC survey 
includes information on the technological innovation activities of all the main sectors in 
the Spanish economy, including services and manufacturing. Firms are specifically 
asked if they carry out some type of activity (involving production, distribution, sales, 
services and R&D) related to biotechnology, where biotechnology is defined as the 
application of science and technology to live organism or parts of live organism in order 
produce knowledge, goods and services.  This feature of the questionnaire enables us 
to identify, across a variety of sectors, the firms which are active in biotechnology.  
Some of the previous studies use samples of convenience owing to the difficulty to 
identify firms with biotechnology activity; such samples, however, are not likely to be 
statistically representative of the whole biotechnology industry.  
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We use data for the year 2007 which provides information on nearly 12,000 firms.2
 
 In 
this sample, 407 firms carry out some type of bio-technological activity. Table 1 shows 
the distribution of these firms by type of company. We can observe that biotechnology 
firms are more frequently public sector companies, multinational firms and research 
associations compared to non-bio technology firms. 
Table 2 shows the distribution of the firms in the sample by main activity. The sector 
categories are those of CNAE (the Spanish acronym for National Classification of 
Economic Activities), similar to NACE rev 1, the classification of economic activities 
used in EU statistics.  Other studies which analyse R&D alliances and R&D 
outsourcing in biotechnology also survey establishments in a variety of 
sectors(Benneworth, 2003; Suárez-Villa and Walrod, 2003).  As stated, biotechnology 
is an emerging industry spanning over several sectors. The sample biotechnology firms 
operate mainly in the following sectors:  Research and Development; Agriculture and 
Food and Drinks; and Pharmaceutical and Chemical products. The importance of R&D 
firms in the sample is in line with previous studies that note the pronounced rise of 
specialist research firms in biotechnology (Cooke, 2004).  Companies involved in 
production of medical instruments, software and testing are providers of diagnostic kits, 
bioinformatics (e.g. data processing for genetics experiments) and other materials and 
services necessary for biotech research. Biosciences and healthcare are strongly 
intertwined (Cooke, 2004); hence, the substantial presence of health care companies in 
our sample. Our data corroborate the interest in biotechnology shown by a large range 
of companies from different sectors (Alfranca et al., 2004; Powell and Grodal, 2005).  
Also, country-specific factors shape the characteristics of this Spanish industry.  The 
relative importance of the various sectors displayed on Table 2 is in line with results of 
a European survey which includes 49 Spanish firms active in biotechnology (Senker 
and Mangematin, 2008).   The evidence supports these authors’ findings in that agro-
food firms are over-represented in the Spanish biotechnology industry, in accordance 
with the importance of the agro-food sector in Spanish production and exports (Senker 
and Mangematin, 2008).   
 
As stated, in this paper we focus on R&D purchasing and cooperation for innovation 
patterns among firms with biotechnology activity and compare those firms to firms 
without biotechnology activity. As for cooperation activities, only innovation active 
firms3
 
 were asked questions related to their cooperation. For the biotechnology firms, 
these means that for cooperation activities we have responses for 393 firms as only 14 
companies (3.4 %) reported no type of innovative activity. These are 3 public sector 
companies, 7 private domestic companies and 4 multinational companies. These 
companies operate mainly in the wholesale trade (6) and the health and social sector 
(5).  As will be seen below, the low percentage of non innovators reflects the enormous 
importance of innovation for firms active in biotechnology. There are, however, no 
significant size differences between the innovative and non-innovative biotechnology 
firms. Note that for non-biotechnology companies approximately 33% in the sample 
report no innovative activity and thus were not asked the questions regarding 
cooperation for innovations. For this reason, one has to be careful in comparing the two 
groups. We, therefore, check all results presented in the next Section for their 
robustness when we restrict the comparison to innovative active firms. 
Appendix 1 displays the variables used in the analysis.   
                                                 
2 We use the anonymized data set that is freely available. López (2010) compares regression 
results based on the anonymized and original data and shows that using the anonymized data 
from PITEC produces reliable results. 
3 Firms that have at least introduced new products or new processes or that have innovative 
activities ongoing or abandoned during the two years prior to the survey date. 
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4. Empirical results 
 
We start our analysis with R&D sourcing relations through the external purchasing of 
R&D services before we present our results for R&D cooperation. 
 
In Table 3, we can see that among non biotechnology firms 76 percent of firms do not 
report any external purchasing of R&D services. In contrast, biotechnology firms 
purchase to a greater extent R&D services from other firms. The percentage of firms 
that report no purchases of R&D is much lower with 43.7 percent. From the remaining 
firms that do report purchasing of R&D services, we see that R&D purchasing is still 
dominantly domestic. Nevertheless, among biotechnology firms a greater percentage 
engages in international R&D sourcing.  About 12 percent of these firms report to 
purchase R&D services in the international markets. Repeating the comparison for only 
innovative active firms reduces the differences between biotechnology firms and others 
only slightly and in all cases the significances of t-tests reported remain unchanged. 
 
As stated, Table 3 shows that most firms that purchases R&D do so in the domestic 
market. In Table 4 we compare domestic and foreign sourcing relations in 
biotechnology firms and non-biotechnology firms according to the type of supplier of 
the technology. Do biotechnology firms source from different technology suppliers? 
Panel A compares the location of the technology supplier (domestic or foreign) for 
different types of suppliers. Relations with other companies and universities involve 
more frequently a foreign supplier in the case of biotechnology firms compared to non-
biotechnology firms.  Again, the results remain qualitatively unchanged when we 
restrict the sample to innovative active firms only. In Panel B we compare the type of 
technology supplier in domestic and foreign relations. Foreign relations in non-
biotechnology firms are to a much greater extent within the same company group. In 
contrast, biotechnology firms show a greater propensity to source technology from 
foreign public administrations and universities. In domestic relations, non-biotechnology 
firms source technology above all from other companies while biotechnology firms 
source technology more frequently from universities and public administrations than 
non-biotechnology firms also in domestic relations.  Again, repeating the comparison 
for innovative active firms only changes percentages marginally in the case of domestic 
sourcing, but does not change significances of t-tests reported. All firms with foreign 
purchases of R&D are at the same time innovative active firms, thus comparisons 
between biotechnology firms and non-biotechnology firms remain unchanged. 
 
So far we have shown that there are some significant differences in the patterns of 
R&D sourcing between biotechnology and non-biotechnology firms. We have also 
shown that these differences persist even when we restrict the sample to innovative 
active firms. Nevertheless, differences in the pattern of R&D sourcing could also be 
due to other differences in the characteristics of biotechnology firms and non-bio- 
technology firms.  
 
In Table 5 we present some controlled associations between R&D sourcing and a 
number of firm and industry characteristics for innovative active firms. We carry out 
probit estimations where the dependent variables are binary indicating, respectively, 
whether or not the firm purchases R&D services (column 1 to 3)  and if yes whether or 
not it does so in the international market (column 4 to 7). We present different 
specifications for each dependent variable. Our variable of interest is a dummy 
indicating whether or not the firm carries out bio-technological activities. As for other 
firm characteristics, in all columns we control for the size of the firm by including the 
number of employees. We also include the number of R&D employees as internal R&D 
activity and external R&D purchases could be substitutes or complements in the 
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innovation process. Other firm characteristics that we include are a dummy whether or 
not the firm belongs to a group, a dummy whether or not the firm belongs to a 
multinational company, a dummy whether or not the company has its headquarters in 
Spain and four regional dummies respectively for location of R&D activities in the main 
industrial agglomerations in Spain (Madrid, Cataluña, Pais Vasco or Valencia). 
Location in those regions could induce a different sourcing behaviour compared to 
peripheral locations. Also, proximity to the border may facilitate R&D collaboration with 
foreign partners (Okubo and Zitt, 2004). In column (2), (3) and (5) to (7) we have added 
the export status of the firm. In column (3) and (6) we have also added two variables 
which attempt to measure obstacles to innovating:  high innovation costs and lack of 
cooperation partners.  These obstacles to innovation are likely to affect the decision to 
purchase R&D services but as we argue below should not influence the decision on the 
location of supplier (domestic versus abroad). All estimations control for industry fixed 
effects. 
 
The results in column (1) to (3) in Table 5 show that biotechnology firms indeed show a 
greater propensity to purchase R&D externally even if we control for other firm and 
industry characteristics. However biotechnology firms show no statistically significant 
greater propensity to purchase R&D services from foreign suppliers once we control for 
other firm and industry characteristics (column (4) to (6)). Here, however, we face a 
classical selection problem in so far that our dependent variable is only observed for a 
non-random sample of firms that engages in R&D purchasing. This could result in 
biased estimations. Heckman (1979) provides a two-stage method to correct for such 
selection bias. The first stage estimates the probability that firms engage in R&D 
purchasing. In the second stage, estimates are corrected for self-selection by 
incorporating a transformation of the predicted probabilities as an additional 
explanatory variable.4
 
 We include the two obstacles to innovation as additional 
variables in the selection equation. The results in column (3) and (6) show that these 
factors relate significantly to the decision to purchase R&D services but not to the 
decision of where to source the services.  The corresponding results from the Heckman 
probit model are shown in column 7 and confirm that biotechnology firms do show a 
greater propensity to purchase R&D services from abroad once we control for firm and 
industry characteristics as well as selection bias. 
We now turn to cooperation for innovation. Note, that the survey only asked innovative 
active firms questions regarding their cooperation behaviour. Thus, results regarding 
cooperation are only based on those firms. In Table 6 we can see that biotechnology 
firms engage more frequently in cooperation for innovation than non-biotechnology 
firms.5
 
  As for the percentage of firms with only domestic cooperation for innovation we 
do not find a significant difference among the two. However, when we look at firms 
which report foreign cooperation we see that a significantly higher percentage of 
biotechnology firms is engaged in international cooperation for innovation. While about 
55% of the biotechnology firms in the sample report having either only foreign or 
foreign and domestic relations of cooperation for innovation this percentage is nearly 
half (28%) in the case of firms with no-biotechnology activity. 
In Tables 7 we present information regarding the type of cooperation partner and the 
location of the partner (in the domestic market, in Europe, in the USA or in other 
countries). Table 7a presents the raw numbers and column and row percentages. In 
Table 7b we present test results for statistical significance of differences between 
biotechnology firms and non-biotechnology firms. In Panel A we test for differences in 
                                                 
4 We estimate this model by using the heckprob command in STATA. 
5 To put these figures into perspective, note that 59% of  Spanish biotechnology firms 
collaborate versus 66% of US biotechnology firms (Súarez-Villa and Walrod, 2003)  
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the spatial pattern of cooperation between biotechnology firms and non-biotechnology 
firms in each type of cooperation. A significantly higher percentage of biotechnology 
firms shows more long-distance cooperation with partners outside Spain and Europe. 
This holds for each type of cooperation partner, except for cooperation for innovation 
with competitors and other firms in the same sector. In Panel B we present significance 
test for differences in the type of partner in each of the four geographical cooperation 
markets. The main differences exist again in the more distant cooperation markets. In 
Europe, patterns are similar with the only exception that biotechnology firms tend to 
operate to a greater degree with European universities. Specifically for the USA we see 
that biotechnology firms show a more varied pattern of cooperation partners, whereas 
cooperation of non-biotechnology firms with the USA are mostly within the same 
company group or with private R&D labs. 
 
In Table 8 we present again some controlled associations between cooperation for 
innovation and the set of firm and industry characteristics we analysed in Table 5. We 
run again probit estimations. Now the dependent variables are, respectively, whether or 
not the firm cooperates for innovation (column 1 to 3) and if yes whether or not it does 
so in the international market (column 4 to 7). In columns (1), (2), (4) and (5) we use 
the same set of explanatory variables as in Table 5 in the corresponding columns. In 
column (3) and (5) we have again added two variables which attempt to measure  
obstacles to innovating:  lack of qualified personnel and lack of information about 
technology and we expect to influence the cooperation decision but not the decision of 
the location of cooperation partner. The results in Table 8 show that biotechnology 
firms show a greater propensity to carry out cooperation for innovation even if we 
control for other firm and industry characteristics (column (1) to (3)). The results in 
column (4) to (6) also indicate that biotechnology firms show a greater propensity to 
cooperate with foreign partners. However, once we control for sample selection, the 
results in column (7) show no higher propensity of biotechnology firms to cooperate 
with foreign partners. Again, we have included the two variables capturing obstacles to 
innovation in the selection equation.6
 
 Note, that in all the estimations results reported 
are based on estimations that include detailed sector dummies. Thus, results show that 
within the same sector, those firms that report biotechnology activities are not more 
prone to cooperate with foreign partners. Repeating these estimations without sector 
control, does, however show a slightly significant positive coefficient for the 
biotechnology dummy. This reflects, that as a whole biotechnology firms cooperate 
more with foreign partners, however not more than firms in the same sectors without 
biotechnology activity. 
 
5.  Discussion 
 
Compared to other firms, biotechnology firms display a greater propensity to purchase 
external R&D and to engage in cooperation for innovation, even when other 
characteristics of companies are controlled for. This finding supports, with a large 
sample at the national level, results of previous studies which are mostly based on 
case-studies of world’s leaders in the biotechnology industry (Hopkins et al., 2007; 
Powell and Grodal, 2005).  
 
There are also differences concerning the firms’ partners in R&D cooperation and their 
suppliers of technology.  Biotechnology firms are more likely to source technology from 
                                                 
6 Note that results remain qualitatively unchanged when only the lack of qualified personnel 
dummy is included as additional variable in the selection equation. Results are also unchanged, 
if for example, the high innovation cost dummy variable used in Table 5 together with the lack of 
qualified personnel dummy is included. 
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public institutions (as opposed to companies) both by engaging in R&D cooperation 
with them or by purchasing R&D services from them.  This finding is in line with the 
idea that the rise in the commercialisation of university knowledge is associated, 
among other causes, with the emergence of the biotechnology industry (Rasmussen et 
al., 2006). On the other hand, our finding on the importance of institutional partners in 
R&D cooperation is in accordance with findings for the US biotechnology industry 
(Bagchi-Sen, 2004).  It is true that, compared with other European universities, Spanish 
universities are much more oriented towards teaching as opposed to research 
(Bonaccorsi and Daraio, 2009).  Nevertheless, our results are coherent with another 
study.  Out of 47 Spanish universities, Gómez et al. (2009) find four universities 
specialising in Agriculture-Biology-Environment-Biomedicine; these universities 
displayed high levels of cooperation with private companies, as measured by co-
authored ISI publications.  On the other hand, as noted by a study on this industry in 
North East England, biotechnology firms may also have links with non life science 
university departments, such as engineering departments (Benneworth, 2003). In spite 
of the importance of R&D private labs in current fundamental research in biotechnology 
(Cooke, 2004), the sample biotechnology firms are significantly less likely than other 
sample firms to collaborate with such labs in Spain or in “other countries” (differences 
between both types of Spanish firms concerning R&D partners located in the rest of 
Europe and the USA are statistically not significant). 
 
Previous research has shown that biotechnology firms display a relatively high 
proportion of R&D alliances with foreign firms (Suárez-Villa and Walrod, 2003).  
However, our results suggest that biotechnology firms’ high rates of foreign R&D 
collaboration may actually reflect general patterns of collaborative behaviour in the 
respective sectors of such companies.  Spanish biotechnology firms are not more 
involved in foreign R&D alliances than firms of the same sector with no biotechnology 
activities. It may well be that, following international trends in the biotechnology industry 
(Cooke, 2004), the sample firms rather participate in regional R&D networks.  This 
trend could favour domestic linkages.  However, this hypothesis could not be tested 
with the available evidence. 
 
By contrast, the nature of the respective foreign partners and the geographic scope of 
collaboration differ.  When they cooperate with European partners, biotechnology firms 
are more likely to interact with universities. In spite of the strengthening of Spanish 
research in agro-food biotechnology (Senker and Mangematin, 2008), a possible 
reason is that these companies are not able to find in Spanish universities all the 
scientific resources they may need. As noted by Powell (2005), in biotechnology, 
linkages to universities and research centres which are at the forefront of basic science 
are highly necessary. Analysing co-authored ISI production, Okubo and Zitt (2004) note 
that Spain’s scientific collaborations display a high level of  Europeanization (as 
measured by the share of scientific collaboration with 15 Member States). As a 
consequence, a special high level of European collaborations could have been 
expected on the part of Spanish biotechnology firms -- given that biotechnology is a 
science-based industry.  Nevertheless, with the exception of universities, the level of 
R&D collaboration displayed by Spanish biotechnology firms with European partners 
seems comparable to that shown by the rest of the sample companies.  This situation 
may be an indirect indication that, as claimed by some authors, Europe is weak in 
science and technology related to biotechnology and other fast growing fields (Lundvall 
and Borrás, 2005).  As will be seen below, the situation is quite different concerning the 
R&D collaboration of the sample biotechnology firms with US partners. 
 
We find that biotechnology firms are more likely than other companies to engage in 
transatlantic partnerships.  Our results are similar to Miotti and Sachwald’s (2003) who 
note that French firms which research at the technological frontier are more inclined to 
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engage in transatlantic collaborations. In specific fields of the life sciences, the 
resources put to the disposal of research are greater in the USA than in any other 
country; and public stimulus to university- firms networking is substantial in the USA 
(Cooke, 2004; Salter and Salter, 2010). Previous research shows that many European 
leading pharmaceutical companies are tapping into US biotechnology research through 
R&D alliances and other methods (Lazonick and Tulum, 2009). Our results suggest 
that this strategy may be more extended than believed. According to our findings, 
Spanish biotechnology firms of all sizes, even those coming from sectors other than 
pharmaceuticals, are tapping into such US resources mainly through R&D 
collaborations with US universities and, especially, R&D private labs.   
 
 
 
6. Conclusions 
 
In this paper we have studied the technology sourcing behaviour of biotechnology firms 
and firms that are not engaged in biotechnological activities We find some significant 
differences between their respective patterns of technology sourcing. Compared to 
other firms, even to those operating in their same sector, biotechnology firms are more 
inclined to engage in open innovation and in network- based governance of R&D. Their 
preferences for a heterogeneity of interfaces with different types of partners and 
suppliers suggests a substantial search investment.  
 
Biotechnology firms are also more likely than other firms in their respective sector to 
purchase R&D from abroad but not to establish cooperation for innovation with foreign 
partners. However, their sources of foreign technology are more varied both 
concerning the types of agents and the geographic origin of technology.  This finding 
confirms that biotechnology firms organize innovation differently from other companies, 
including firms with no biotechnology activities pertaining to their own origin sector.   
 
Our results show the need to specifically focus on emerging industries in order to 
formulate policies concerning innovation.  Processes of learning display a collective 
dimension (Lazonick, 2005; Teece and Pisano, 1994).  Therefore, a systemic approach 
(Malerba, 2005) to innovation policy is needed, especially in industries highly inclined 
to source technology externally as the one studied in this paper. As stated, the 
constellations of actors involved in such learning processes differ in biotechnology 
firms.  Universities, both at home and abroad, seem to play a very important role; 
hence, the need to create stimuli for scientists and universities active in this field both 
at the national and the supra-national levels. Linkages of these institutions with the 
biotechnology industry should be facilitated. At the national level, bureaucratic 
difficulties and insufficient stimuli to university-industry linkages are likely to be 
especially harmful for biotechnology firms.  Also, the managerial burden often involved 
in EU projects (Lundvall and Borrás, 2005) may put breaks to European R&D 
integration in this strategic field, with especially harmful consequences for catching-up 
countries such as Spain. 
 
Finally, it is important to emphasise that the results indicate associations, but should 
not be taken to prove causal relations. Firms make decisions regarding their 
technology sourcing strategy together with decisions concerning their size, internal 
R&D and a series of other company and plant-level characteristics that our cross-
sectional data cannot easily control for. Moreover, international R&D purchasing as 
well international cooperation for innovation can not be viewed in isolation. These 
decisions are part of a firm’s internationalisation strategy that goes hand in hand with 
the exporting decision. 
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Table 1. Biotechnology firms by type of company 
 
 
Biotech 
 firms 
 
Non 
biotech firms 
 
Total 
 
 No % No % No % 
Public sector 16 3.9 236 2.1 252 2.2 
private national 314 77.2 9690 86.6 10004 86.3 
private multinational 55 13.5 1137 10.2 1192 10.3 
research association 22 5.4 124 1.1 146 1.3 
Total 407 100 11187 100 11594 100 
       Pearson chi2(3) =  71.9435   Pr = 0.000 
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Table 2. Biotechnology firms by type of main activity 
 
 
Biotech 
 firms 
 
Non 
biotech firms 
 
Total 
 
 No % No % No % 
Agriculture 42 10.3 129 1.2 171 1.5 
Food and drinks 57 14.0 697 6.23 754 6.5 
Paper 4 1.0 109 1.0 113 1.0 
Chemical products 38 9.3 566 5.1 604 5.2 
Pharmaceutical products 40 9.8 124 1.1 164 1.4 
Rubber and plastic materials 2 0.5 370 3.3 372 3.2 
Non-metallic mineral products 2 0.5 290 2.6 292 2.5 
Machinery and mechanical equipment 3 0.7 807 7.2 810 7.0 
Machinery and electrical equipment 1 0.3 283 2.5 284 2.5 
Medical instruments, optical and precision equipment 8 2.0 240 2.1 248 2.1 
Recycling 1 0.3 41 0.4 42 0.4 
Production and distribution of energy 6 1.5 73 0.7 79 0.7 
Construction 4 1.0 463 4.1 467 4.0 
Wholesale trade 20 4.9 544 4.9 564 4.9 
Retail trade 1 0.3 202 1.8 203 1.8 
Accommodation 2 0.5 186 1.7 188 1.6 
Finance 1 0.3 216 1.9 217 1.9 
Software 2 0.5 637 5.7 639 5.5 
Other computer programming activities 1 0.3 183 1.6 184 1.6 
Research and development 91 22.4 215 1.9 306 2.6 
Architecture and engineering activities 11 2.7 435 3.9 446 3.9 
Testing and technical analysis 23 5.7 123 1.1 146 1.3 
Other business activities 5 1.2 688 6.2 693 6.0 
Education 1 0.3 55 0.5 56 0.2 
Other health and social activities 41 10.1 437 3.9 478 4.1 
Other sectors with no biotechnology firms   3074 27,5   
Total 407 100 11187 100 11594 100 
Pearson chi2(55) =  1.4e+03   Pr = 0.000 
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Table 3. External R&D sourcing 
 
 
Biotech  firms 
 
 Non 
biotech  firms 
t-test of means 
difference sig. 
 No %  No %   
No external R&D sourcing 178 43.7  8.505 76.0 14.896 *** 
Only domestic external R&D sourcing 181 44.5  2.265 20.2 -11.836 *** 
Only foreign external R&D sourcing 6 1.5  127 1.1 -0.630  
Domestic and foreign external R&D sourcing 42 10.3  290 2.6 -9.214 *** 
Total 407 100.0  11.187 100.0   
Note: *** significant at the 1% level; ** significant at the 5% level; *significant at the 10% level 
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Table 4. Domestic versus international R&D sourcing relations by type of technology supplier 
 
Panel A: significance test for differences between domestic and international technology suppliers 
 Biotech firms Non biotech firms   
 Domestic foreign total domestic foreign total t-test  sig. 
Type of R&D partner No % No %  No % No %    
             
intra-group 21 77.8 6 22.2 27 248 65.4 131 34.6 379 -1.310  
other companies 127 77.4 37 22.6 164 1.587 86.0 259 14.0 1846 2.959 *** 
public administration 62 92.5 5 7.5 67 170 93.4 12 6.6 182 0.240  
Universities 115 89.1 14 10.9 129 800 95.6 37 4.4 837 3.052 *** 
private non-profit organisations 18 81.8 4 18.2 22 186 92.1 16 7.9 202 1.605  
other research organisations 47 95.9 2 4.1 49 552 97.5 14 2.5 566 0.678  
Total 390 85.2 68 14.8 458 3543 84.4 469 15.6 4012   
 
Panel B: significance test for differences between the type of technology supplier 
 Biotech firms  Non biotech  firms domestic foreign 
 domestic foreign  domestic foreign t-test  sig. t-test  sig. 
Type of R&D partner % %  % %      
           
intra-group 5,4 8,8  7,0 27,9  1.199  3.408 *** 
other companies 32,6 54,4  44,8 55,2  4.634 *** 0.125  
public administration 15,9 7,4  4,8 2,6  -8.917 *** -2.115 ** 
Universities 29,5 20,6  22,6 7,9  -3.067 *** -3.367 *** 
private non-profit organisations 4,6 5,9  5,2 3,4  0.536  -1.005  
other research organisations 12,1 2,9  15,6 3,0  1.841 *   0.020  
Total 100,0 100,0  100,0 100,0      
Note: multiple responses; categories are not exclusive.*** significant at the 1% level; ** significant at the 5% level; *significant at the 10% level 
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Table 5. Controlled associations for R&D purchases 
 
 
R&D purchases R&D foreign purchases 
 (1) (2) (3) (4) (5) (6) (7) 
 
Biotechnology 
0.474*** 
(0.071) 
0.458*** 
(0.071) 
0.448*** 
(0.072) 
 0.070 
(0.117) 
 0.047 
(0.118) 
 0.050 
(0.118) 
0.242*** 
(0.100) 
number of employees (in 1000) 
0.004 
(0.011) 
0.004 
(0.011) 
0.005 
(0.011) 
-0.030 
(0.030) 
-0.030 
(0.031) 
-0.030 
(0.031) 
-0.015 
 (0.024) 
number of R&D employees 
0.003*** 
 (0.0005) 
0.003*** 
 (0.0005) 
0.003*** 
 (0.0005) 
0.006*** 
 (0.001) 
0.005*** 
 (0.001) 
0.005*** 
 (0.001) 
0.005*** 
 (0.001) 
firm belongs to a group 
0.089 
(0.070) 
0.068 
(0.070) 
0.106 
(0.070) 
0.832*** 
(0.129) 
0.807*** 
(0.130) 
0.784*** 
(0.131) 
0.637*** 
(0.099) 
multinational company 
0.017 
(0.074) 
 0.002 
(0.074) 
-0.001 
(0.074) 
0.185 
(0.131) 
0.165 
(0.131) 
0.171 
(0.132) 
 0.093 
(0.099) 
headquarter in Spain 
0.201*** 
(0.072) 
0.208*** 
(0.072) 
0.179** 
(0.072) 
-0.562*** 
(0.128) 
-0.556*** 
(0.129) 
-0.536*** 
(0.130) 
-0.309*** 
 (0.099) 
firm is exporting 
 0.198*** 
(0.035) 
0.196*** 
(0.036) 
 0.408*** 
(0.088) 
0.410*** 
(0.088) 
0.421*** 
(0.071) 
Madrid 
0.366*** 
(0.048) 
0.345*** 
(0.048) 
0.341*** 
(0.048) 
-0.017 
(0.092) 
-0.036 
(0.093) 
-0.024 
(0.093) 
0.142** 
(0.074) 
Cataluña 
0.270*** 
(0.038) 
0.243*** 
(0.039) 
0.247*** 
(0.039) 
0.110 
(0.075) 
0.086 
(0.076) 
0.085 
(0.076) 
0.173*** 
(0.058) 
Pais Vasco 
0.613*** 
(0.048) 
0.607*** 
(0.048) 
0.598*** 
(0.048) 
-0.250*** 
(0.097) 
-0.249*** 
(0.097) 
-0.244** 
(0.097) 
0.074 
(0.082) 
Valencia 
0.537*** 
(0.054) 
0.522*** 
(0.054) 
0.518*** 
(0.054) 
-0.137 
(0.105) 
-0.155 
(0.105) 
-0.140 
(0.105) 
0.116 
(0.087) 
Obstacle to innovating: high 
innovation cost 
  0.064** 
(0.032) 
  -0.086 
(0.067) 
 
Obstacle to innovating:  lack of 
cooperation partners 
  0.156*** 
(0.031) 
  -0.019 
(0.066) 
 
No of observations 8709 8709 8709 2885 2885 2885 8709 
Log likelihood -5137.1 -5121.3 -5103.2 -1081.7 -1070.5 -1069.5 -6165.45 
Pseudo R2 0.071 0.074 0.077 0.151 0.160 0.161  
Rho       -0.986*** 
Note: .*** significant at the 1% level; ** significant at the 5% level; *significant at the 10% level; all estimations include 26 sector dummies. Column 
(7) presents results from the Heckman selection model using STATA command heckprob where the selection equation includes the two dummies for 
innovation hindering factors: high innovation cost and lack of cooperation partners. 
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Table 6. Cooperation for innovation among innovation active firms 
 
 
Biotech firms 
 
 Non 
biotech firms 
t-test of means 
difference sig. 
 No %  No %   
No cooperation for innovation 161 41.0  5.555 66.8 10.603 *** 
Only domestic cooperation for innovation 14 3.6  453 5.4 1.621  
Only foreign cooperation for innovation 120 30.5  1.238 14.9 -8.388 *** 
Domestic and foreign cooperation for innovation 98 24.9  1.070 12.9 -6.879 *** 
Total 393 100.0  8.316 100.0   
Note: *** significant at the 1% level; ** significant at the 5% level; *significant at the 10% level 
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Table 7a. Domestic versus international cooperation for innovation.  Location of partners 
 
Biotechnology domestic C% 
  
R%  Europe C% 
  
R%  USA  C% 
  
R%  other C% 
  
R%  Total  
intra-group 46 26,0 14,6 68 33,3 21,6 89 24,7 28,3 112 42,6 35,6 315  
Supplier 19 10,7 18,1 27 13,2 25,7 33 9,2 31,4 26 9,9 24,8 105  
Client 9 5,1 30,0 4 2,0 13,3 12 3,3 40,0 5 1,9 16,7 30  
competitor or other firms in the sector 1 0,6 4,0 11 5,4 44,0 7 1,9 28,0 6 2,3 24,0 25  
private R&D labs 56 31,6 16,2 52 25,5 15,1 150 41,7 43,5 87 33,1 25,2 345  
Universities 29 16,4 22,7 33 16,2 25,8 44 12,2 34,4 22 8,4 17,2 128  
public research organisations 12 6,8 37,5 6 2,9 18,8 13 3,6 40,6 1 0,4 3,1 32  
technology centres 5 2,8 20,8 3 1,5 12,5 12 3,3 50,0 4 1,5 16,7 24  
Total 177 100 17,6 204 100 20,3 360 100 35,9 263 100 26,2 1004  
non-biotechnology                          
intra-group 535 22,7 20,6 745 39,9 28,7 763 32,2 29,4 550 30,1 21,2 2593  
Supplier 242 10,3 32,7 251 13,5 34,0 152 6,4 20,6 94 5,2 12,7 739  
Client 57 2,4 42,2 50 2,7 37,0 19 0,8 14,1 9 0,5 6,7 135  
competitor or other firms in the sector 49 2,1 34,8 57 3,1 40,4 16 0,7 11,3 19 1,0 13,5 141  
private R&D labs 1011 42,9 27,4 490 26,3 13,3 1176 49,7 31,8 1017 55,7 27,5 3694  
Universities 352 14,9 40,6 206 11,0 23,8 192 8,1 22,2 116 6,4 13,4 866  
public research organisations 66 2,8 53,2 28 1,5 22,6 23 1,0 18,5 7 0,4 5,6 124  
technology centres 44 1,9 35,8 39 2,1 31,7 27 1,1 22,0 13 0,7 10,6 123  
Total 2356 100 28,0 1866 100 22,2 2368 100 28,1 1825 100 21,7 8415  
Note: multiple responses; categories are not exclusive.  
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Table 7b. Comparing location and type of cooperation partner 
 
Panel A: significance tests for differences in location 
 domestic sig. Europe sig. USA sig. other sig.  
intra-group 0.528  0.658  0.649  0.000 ***  
Supplier 0.097  1.000  0.000 *** 0.000 ***  
Client 1.000  0.096 * 0.001 *** 0.163   
competitor or other companies in the sector 0.003 *** 1.000  0.116  0.765   
private R&D labs 0.000 *** 0.564  0.000 *** 1.000   
Universities 0.001 *** 0.727  0.000 *** 0.293   
public research organisations 1.000  1.000  0.006 *** 1.000   
technology centres 0.315  0.109  0.022 ** 1.000   
 
Panel B: significance tests for differences in type of partner 
 domestic sig. Europe sig. USA sig. other sig.  
intra-group 1.000  1.000  1.000  0.000 ***  
Supplier 1.000  1.000  0.003 *** 0.000 ***  
Client 0.207  1.000  0.000 *** 0.017 **  
competitor or other companies in the sector 1.000  0.164  0.011 ** 0.221   
private R&D labs 0.004 *** 1.000  0.122  0.000 ***  
Universities 1.000  0.010 *** 0.000 *** 0.247   
public research organisations 0.018 ** 0.431  0.000 *** 1.000   
technology centres 1.000  1.000  0.000 *** 0.644   
Note: multiple responses; categories are not exclusive. Significance is based on Pearson chi2 p-value: *** significant at the 1% level; ** 
significant at the 5% level; *significant at the 10% level 
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Table 8. Controlled associations for cooperation for innovation  
 
 
Cooperation for innovation Foreign cooperation for innovation 
 (1) (2) (3) (4) (5) (6) (7) 
 
Biotechnology 
0.418*** 
(0.071) 
0.408*** 
(0.072) 
0.410*** 
(0.072) 
 0.351** 
(0.153) 
 0.331** 
(0.153) 
 0.332** 
(0.153) 
 0.100 
(0.133) 
number of employees (in 1000) 
0.013 
(0.011) 
0.013 
(0.011) 
0.014 
(0.011) 
-0.024 
(0.016) 
-0.023 
(0.016) 
-0.023 
(0.016) 
-0.029** 
(0.013) 
number of R&D employees 
0.006*** 
 (0.001) 
0.006*** 
 (0.001) 
0.006*** 
 (0.001) 
0.004*** 
 (0.001) 
0.004*** 
 (0.001) 
0.004*** 
 (0.001) 
0.002** 
 (0.001) 
firm belongs to a group 
0.216*** 
(0.069) 
0.198*** 
(0.069) 
0.221*** 
(0.069) 
-0.784*** 
(0.130) 
-0.808*** 
(0.130) 
-0.803*** 
(0.130) 
-0.716*** 
(0.097) 
multinational company 
-0.032 
(0.073) 
-0.043 
(0.073) 
-0.036 
(0.073) 
0.041 
(0.135) 
0.035 
(0.135) 
0.039 
(0.135) 
0.101 
(0.099) 
headquarter in Spain 
0.106 
(0.070) 
0.113 
(0.070) 
0.100 
(0.071) 
 0.479*** 
(0.129) 
 0.489*** 
(0.129) 
 0.486*** 
(0.129) 
 0.317*** 
(0.096) 
firm is exporting 
 0.160*** 
(0.035) 
0.155*** 
(0.035) 
 0.213*** 
(0.076) 
0.212*** 
(0.076) 
0.055 
(0.056) 
Madrid 
0.227*** 
(0.048) 
0.209** 
(0.048) 
0.213*** 
(0.048) 
  0.208** 
(0.098) 
  0.183* 
(0.099) 
  0.183* 
(0.099) 
  0.040 
(0.080) 
Cataluña 
0.076** 
(0.039) 
0.054 
(0.039) 
0.055 
(0.039) 
0.055 
(0.079) 
0.038 
(0.079) 
0.036 
(0.079) 
0.001 
(0.061) 
Pais Vasco 
0.561*** 
(0.048) 
0.557*** 
(0.048) 
0.548*** 
(0.048) 
 0.360** 
(0.099) 
 0.352*** 
(0.099) 
 0.353*** 
(0.099) 
 0.001 
(0.083) 
Valencia 
0.210*** 
(0.055) 
0.197*** 
(0.055) 
0.199*** 
(0.055) 
 0.068 
(0.113) 
 0.053 
(0.113) 
 0.053 
(0.113) 
-0.055 
(0.091) 
Obstacle to innovating: lack of 
qualified personnel 
  0.141*** 
(0.034) 
   0.058 
(0.071) 
 
Obstacle to innovating:  lack of 
information about technology 
  0.031 
(0.035) 
  -0.012 
(0.073) 
 
No of observations 8709 8709 8709 2993 2993 2993 8709 
Log likelihood -5214.5 -5204.0 -5189.0 -1148.4 -1144.5 -1144.1 -6324.0 
Pseudo R2 0.070 0.071 0.074 0.114 0.117 0.117  
Rho       -0.999*** 
Note: .*** significant at the 1% level; ** significant at the 5% level; *significant at the 10% level; all estimations include 26 sector dummies. Column 
(7) presents results from the Heckman selection model using STATA command heckprob where the selection equation includes the two dummies for 
innovation hindering factors: lack of qualified personnel and lack of information technology. 
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Appendix 1.  Description of variables 
Name of variable Survey question, responses, and measurement :  
    External 
sourcing of R&D 
Purchase of R&D 
services external to 
the firm through 
contracts or other 
arrangements (in € 
before taxes) 
From: 
1. Enterprises of the same group 
2. Other companies 
3. Public Administration 
4. Universities 
5. Private non-profit organisation 
5. Other research organisation  
For each response, 
the surveyed 
company was asked 
to indicate the 
location of seller : 
1. Spain 
2. Foreign country 
Cooperation for 
innovative 
activities 
In 2005-2006, has your firm cooperated with other 
firms or with institutions to carry out innovative 
activities? (subcontracting excluded) 
 
 
 
1 =Yes 
0 = No 
Type of partner Indicate the type of 
partners with whom 
you cooperated and 
the countries where 
they are located 
1. Other companies of your group  
2. Suppliers of equipment, 
components or software 
3. Clients 
4. Competitors or other sector 
companies 
5. Consultants, commercial labs 
or private R&D centres 
6. Universities or other high 
education institutions 
7. Public research centres 
8. Technological centres 
For each response, 
the surveyed 
company was asked 
to indicate the 
location of partner: 
1.Spain 
2.Other European 
countries (1) 
3.USA 
4. Other countries 
No. of employees No. of employees of the company   
No. of R&D 
employees 
No. of R&D employees of the company   
Group Does your firm belong to a business group?  1 =Yes 
0 = No 
Multinational 
company 
Type of company Private company with at least 
50% foreign ownership 
1 =Yes 
0 = No 
Headquarters in 
Spain 
Where are the headquarters of your business group?  
 
1= Spain 
0= other countries 
Firm is exporting In what geographic markets 
have you sold production in 
2005-2007? 
1. Local or regional 
2. National 
3. International market 
1= if the firm reports 
sales in the international 
market 0=otherwise 
Location of main 
laboratory  
No. of R&D employees by 
region: 
17 Autonomous regions 
 Dummies for Madrid, Cataluña, País Vasco, 
and Valencia =1 if R&D employment >0, 
and zero otherwise. (2) 
Obstacles to 
innovation 
Indicate the 
importance of factors 
that make innovation 
difficult. 
1. High innovation cost 
2. Lack of qualified personnel 
3. Lack of information about 
technology 
Ratings of importance: 
high, intermediate, 
reduced, not relevant. 
Dummies for values of 
high and intermediate 
=1 and zero otherwise. 
Notes: (1) Includes EU-27, Switzerland and Turkey. (2) Alternatively the regional dummies have been based 
on the location of the main R&D centre (R&D employment >50%). Results are qualitatively unchanged. 
 
